Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Amortization - Intangibles (2016 - 2025)

Vanda Pharmaceuticals (VNDA) has disclosed Amortization - Intangibles for 16 consecutive years, with $1.8 million as the latest value for Q4 2025.

  • Quarterly Amortization - Intangibles fell 1.18% to $1.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.1 million through Dec 2025, down 3.65% year-over-year, with the annual reading at $7.0 million for FY2025, 3.66% down from the prior year.
  • Amortization - Intangibles hit $1.8 million in Q4 2025 for Vanda Pharmaceuticals, down from $1.8 million in the prior quarter.
  • In the past five years, Amortization - Intangibles ranged from a high of $2.0 million in Q1 2024 to a low of $370000.0 in Q3 2021.
  • Historically, Amortization - Intangibles has averaged $984500.0 across 5 years, with a median of $400000.0 in 2021.
  • Biggest five-year swings in Amortization - Intangibles: soared 427.7% in 2024 and later decreased 12.4% in 2025.
  • Year by year, Amortization - Intangibles stood at $378000.0 in 2021, then grew by 0.26% to $379000.0 in 2022, then soared by 161.21% to $990000.0 in 2023, then skyrocketed by 79.09% to $1.8 million in 2024, then decreased by 1.18% to $1.8 million in 2025.
  • Business Quant data shows Amortization - Intangibles for VNDA at $1.8 million in Q4 2025, $1.8 million in Q3 2025, and $1.8 million in Q2 2025.